Compound Evidence File
#EC-2026-0921
Flibanserin
Filed under Oral Tablets. The bureau holds 113 laboratory returns for this compound from 35 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
35 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 6 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 4 | 10.0 | 9.9 | 10.0 | 13 Feb 2026 | 5 Jul 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 4 | 10.0 | 9.9 | 10.0 | 15 Nov 2025 | 1 Jul 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 4 | 10.0 | 9.9 | 10.0 | 21 Feb 2026 | 20 Jun 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 3 | 10.0 | 9.9 | 10.0 | 5 May 2026 | 8 Jul 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 3 | 10.0 | 9.9 | 10.0 | 2 May 2026 | 13 Jun 2026 |
| AsymchemCASE #VI-2026-0091 | A | 3 | 10.0 | 9.9 | 10.0 | 6 May 2026 | 7 Aug 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 6 | 9.9 | 9.9 | 10.0 | 21 May 2026 | 21 May 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 4 | 9.9 | 9.9 | 10.0 | 1 Mar 2026 | 26 Jun 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 4 | 9.9 | 9.9 | 10.0 | 8 Apr 2026 | 3 Jul 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 4 | 9.9 | 9.9 | 10.0 | 25 Jan 2026 | 4 Jun 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 4 | 9.9 | 9.9 | 10.0 | 7 May 2026 | 5 Aug 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 4 | 9.9 | 9.9 | 10.0 | 16 Feb 2026 | 25 Jul 2026 |
| SinoPepCASE #VI-2026-0387 | A | 4 | 9.9 | 9.9 | 10.0 | 11 Mar 2026 | 2 Aug 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 3 | 9.9 | 9.9 | 10.0 | 28 Mar 2026 | 22 May 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 3 | 9.9 | 9.9 | 9.9 | 17 Mar 2026 | 11 Apr 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 3 | 9.9 | 9.9 | 10.0 | 21 Feb 2026 | 9 Jul 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 9.9 | 9.9 | 10.0 | 8 Nov 2025 | 2 May 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 2 | 9.9 | 9.9 | 10.0 | 2 May 2026 | 6 May 2026 |
| BachemCASE #VI-2026-0314 | A | 2 | 9.9 | 9.9 | 10.0 | 13 Mar 2026 | 22 May 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 2 | 9.9 | 9.9 | 9.9 | 12 May 2026 | 12 Jul 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 2 | 9.9 | 9.9 | 10.0 | 11 Jul 2026 | 17 Aug 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 2 | 9.9 | 9.9 | 9.9 | 10 Jul 2026 | 20 Jul 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 2 | 9.4 | 8.8 | 10.0 | 24 May 2026 | 24 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 6 | 9.2 | 8.6 | 10.0 | 21 May 2026 | 21 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 6 | 8.7 | 7.7 | 9.6 | 24 May 2026 | 24 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 3 | 8.2 | 6.8 | 10.0 | 24 May 2026 | 24 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 7 | 7.9 | 6.8 | 9.4 | 24 May 2026 | 24 May 2026 |
| Precision Peptide CoCASE #VI-2026-0559 | X | 1 | 7.5 | 7.5 | 7.5 | 17 Dec 2024 | 17 Dec 2024 |
| Simple PeptideCASE #VI-2026-0782 | X | 2 | 7.0 | 7.0 | 7.1 | 16 Mar 2025 | 26 Jan 2026 |
| UWA Elite PeptidesCASE #VI-2026-0130 | X | 1 | 6.7 | 6.7 | 6.7 | 28 Mar 2025 | 28 Mar 2025 |
| YimeiCASE #VI-2026-0081 | X | 4 | 5.6 | 2.5 | 7.9 | 20 Jun 2025 | 23 May 2026 |
| Yabang PeptideCASE #VI-2026-0148 | X | 1 | 5.4 | 5.4 | 5.4 | 14 Jan 2025 | 14 Jan 2025 |
| Regenerative ResearchCASE #VI-2026-0349 | X | 1 | 5.4 | 5.4 | 5.4 | 3 Jul 2025 | 3 Jul 2025 |
| Weifang Xingbei International TradeCASE #VI-2026-0766 | X | 1 | 0.0 | 0.0 | 0.0 | 21 May 2025 | 21 May 2025 |
Open any subject to view the batch-level evidence for Flibanserin alone.